Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 872912 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $11.58Day +0.26%Mkt cap $400MP/E (FY) 165.4×1Y +6.1%Off 52W high −15.7%Vol (1Y) 47.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,466 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesNEVER-OBSERVED · 130.7% growth |
| Short interest7.8% of sh out |
| Days to cover7.7d |
| 13F net flow (QoQ)−1.66% |
| Top-10 13F concentration66.6% |
| Next report (est.)2026-08-05 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)165.4× |
| Sales (TTM)$90.4M |
| Earnings (TTM)$561,000 |
| ROE3.0% |
| Net margin3.2% |
| ROIC1.0% |
| YTD+14.7% |
| 1Y+6.1% |
| 3Y+164.4% |
| 5Y+17.2% |
| 10Y+172.5% |
| Since incept. (ann.)+11.7% |
Total return through 2026-07-29 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)47.9% |
| Ann. volatility (3Y)79.0% |
| Sharpe (1Y)0.27 |
| Sharpe (3Y)0.77 |
| Max drawdown (1Y)−33.7% |
| Max drawdown (3Y)−60.9% |
| Beta (3Y vs SPY)1.22 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3.3M | $31M | 9.56% | +0.0% |
| BlackRock, Inc. | 1.8M | $17M | 5.17% | −2.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $12M | 3.85% | new |
| Propel Bio Management, LLC | 979,698 | $9M | 2.84% | +123.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 692,031 | $6M | 2.00% | +1.3% |
| STATE STREET CORP | 664,428 | $6M | 1.92% | +9.3% |
| Private Wealth Advisors, LLC | 591,524 | $5M | 1.71% | +103.6% |
| MILLENNIUM MANAGEMENT LLC | 588,055 | $5M | 1.70% | +138.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.03 | −200.0% | $25.0M | +26.3% |
| 2025-12-31 | 2026-02-26 | — | — | $20.7M | +37.3% |
| 2025-09-30 | 2025-11-04 | $0.02 | −66.7% | $20.6M | +83.6% |
| 2025-06-30 | 2025-08-06 | $0.07 | — | $24.2M | +211.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
US 92% · Non Us 8%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Sales growth 3Y215.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
